Enovis (NYSE:ENOV) Trading 10.1% Higher After Strong Earnings

Key Points

• Shares jumped 10.1% intraday after the report, trading as high as $27.73 with 865,582 shares changing hands (about 14% below average session volume).
• Earnings beat: Enovis reported $0.89 EPS vs. $0.82 expected and $589.15M revenue vs. $572.02M expected, and set FY 2026 guidance of 3.520–3.730 EPS.
• Analyst sentiment is broadly positive with a MarketBeat consensus rating of Buy and a $47.43 target, while insiders recently purchased shares and institutional ownership stands at 98.45%.

Enovis Corporation (NYSE:ENOV - Get Free Report) shares traded up 10.1% during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $27.73 and last traded at $27.3560. 865,582 shares changed hands during trading, a decline of 14% from the average session volume of 1,008,345 shares. The stock had previously closed at $24.85.

The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The business's revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ENOV shares. Weiss Ratings restated a "sell (e+)" rating on shares of Enovis in a research report on Friday, April 10th. Wall Street Zen lowered shares of Enovis from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Needham & Company LLC boosted their price target on shares of Enovis from $49.00 to $52.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. BTIG Research boosted their price target on shares of Enovis from $41.00 to $43.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. Finally, Wells Fargo & Company upgraded shares of Enovis to a "strong-buy" rating in a research report on Wednesday, March 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $47.43.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 1,000 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the acquisition, the insider directly owned 43,640 shares in the company, valued at approximately $1,112,820. This trade represents a 2.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased a total of 5,000 shares of company stock valued at $121,983 over the last three months. Company insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Enovis

Several large investors have recently bought and sold shares of ENOV. Rubric Capital Management LP acquired a new position in Enovis in the third quarter valued at approximately $83,435,000. Tributary Capital Management LLC raised its holdings in Enovis by 91.5% in the third quarter. Tributary Capital Management LLC now owns 1,154,482 shares of the company's stock worth $35,027,000 after purchasing an additional 551,613 shares during the period. AQR Capital Management LLC raised its holdings in Enovis by 682.6% in the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company's stock worth $15,627,000 after purchasing an additional 434,646 shares during the period. Paradigm Capital Management Inc. NY raised its holdings in Enovis by 41.6% in the second quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company's stock worth $34,913,000 after purchasing an additional 326,900 shares during the period. Finally, ExodusPoint Capital Management LP raised its holdings in Enovis by 163.4% in the fourth quarter. ExodusPoint Capital Management LP now owns 508,971 shares of the company's stock worth $13,559,000 after purchasing an additional 315,711 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Trading Up 9.8%

The company's fifty day simple moving average is $23.78 and its two-hundred day simple moving average is $25.83. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -1.32 and a beta of 1.41.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.